Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126423812 | 12642381 | 2 | F | 20160810 | 20160810 | 20160819 | EXP | PHHY2016PL108375 | SANDOZ | KLUK MK, WESO?OWSKA K, WORONOWICZ-CHROSCIEL A, WOZAKOWSKA-KAP?ON B. CHALLENGING CHOICES IN PATIENTS AT HIGH RISK OF THROMBOEMBOLIC AND HAEMORRHAGIC COMPLICATIONS ? CLINICAL CASE OF AN 81-YEAR-OLD WOMAN AT HIGH RISK OF CEREBRAL STROKE AFTER GASTROINTESTINAL BLEEDING EPISODE. FOLIA CARDIOLOGICA NR 3/2016 | 81.00 | YR | F | Y | 0.00000 | 20160819 | OT | PL | PL |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126423812 | 12642381 | 1 | PS | RAMIPRIL. | RAMIPRIL | 1 | Unknown | 10 MG, BID | U | 77514 | 10 | MG | BID | ||||||
| 126423812 | 12642381 | 2 | SS | INDAPAMIDE. | INDAPAMIDE | 1 | Unknown | 1.5 MG, QD | U | 0 | 1.5 | MG | QD | ||||||
| 126423812 | 12642381 | 3 | SS | BISOPROLOL | BISOPROLOL | 1 | Unknown | 2.5 MG, QD | U | 0 | 2.5 | MG | QD | ||||||
| 126423812 | 12642381 | 4 | SS | EPLERENONE. | EPLERENONE | 1 | Unknown | 25 MG, QD | U | 0 | 25 | MG | QD | ||||||
| 126423812 | 12642381 | 5 | SS | ATORVASTATIN | ATORVASTATIN | 1 | Unknown | 20 MG, QD | U | 0 | 20 | MG | QD | ||||||
| 126423812 | 12642381 | 6 | SS | DABIGATRAN | DABIGATRAN | 1 | Unknown | 150 MG, BID | Y | 0 | 150 | MG | BID | ||||||
| 126423812 | 12642381 | 7 | SS | AMIODARONE | AMIODARONE | 1 | Unknown | 200 MG, QD | Y | 0 | 200 | MG | QD | ||||||
| 126423812 | 12642381 | 8 | SS | NAPROXEN. | NAPROXEN | 1 | Unknown | 500 MG, 2-3 TIMES DAILY | Y | 0 | 500 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126423812 | 12642381 | 1 | Product used for unknown indication |
| 126423812 | 12642381 | 2 | Product used for unknown indication |
| 126423812 | 12642381 | 3 | Product used for unknown indication |
| 126423812 | 12642381 | 4 | Product used for unknown indication |
| 126423812 | 12642381 | 5 | Product used for unknown indication |
| 126423812 | 12642381 | 6 | Atrial fibrillation |
| 126423812 | 12642381 | 7 | Product used for unknown indication |
| 126423812 | 12642381 | 8 | Arthralgia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126423812 | 12642381 | OT |
| 126423812 | 12642381 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126423812 | 12642381 | Anaemia | |
| 126423812 | 12642381 | Arthralgia | |
| 126423812 | 12642381 | Concomitant disease aggravated | |
| 126423812 | 12642381 | Drug interaction | |
| 126423812 | 12642381 | Gastrointestinal haemorrhage | |
| 126423812 | 12642381 | Renal failure | |
| 126423812 | 12642381 | Shock haemorrhagic |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |